1) docetaxel
多西他赛
1.
Preparation and characteristics of docetaxel nanos-tructure lipid carriers;
多西他赛纳米脂质载体的制备及其性质考察
2.
Determination of Docetaxel and Its Injection by HPLC;
HPLC法测定多西他赛及注射液的含量
3.
Complexation of docetaxel with β-cyclodextrin and HP-β-cyclodextrin;
多西他赛与β-环糊精及羟丙基-β-环糊精包合作用的研究
2) taxotere
多西他赛
1.
Three-weeks’ and weekly taxotere/cisplation treatment in non-small-cell lung cancer;
多西他赛联合顺铂三周方案与每周方案治疗非小细胞肺癌
2.
Concurrent Weekly Taxotere and Three-dimensional Conformal Radiation Therapy for Elderly Patients with Advanced Non-smallCell Lung Cancer
多西他赛同步三维适形放疗治疗老年晚期非小细胞肺癌效果观察
3.
Objective:To assess the efficacy and toxicity of taxotere/cisplatin (TP) and vinorelbine/cisplatin in patients with advanced non-small cell lung cancer (NSCLC).
方法74例进展期非小细胞肺癌,分为TP方案组应用多西他赛加顺铂静脉滴注,NP方案组应用长春瑞滨加顺铂静脉滴注,同时给予水化、利尿等处理,21天为1个周期,4个周期后评价疗效。
3) Docetaxe
多西他赛
1.
Curative Effects of Docetaxe or Oxaliplatin Combined with Xeloda in Advanced Gastric Cancer
多西他赛或奥沙利铂联合希罗达治疗晚期胃癌的疗效对比
2.
Docetaxel combined with Epirubicin and Cytoxan and 5-FU for locally advanced breast cancer neoadjuvant chemotherap
多西他赛联合表柔比星、环磷酰胺和氟尿嘧啶治疗局部晚期乳腺癌
3.
Conclusion:Docetaxel combind with xeloda is active for the patients with anthracycline-resistant metastatic breast canccr,and toxic side effects is acceptably tolerant.
目的:观察希罗达联合多西他赛治疗蒽环类失败复发转移性乳腺癌的临床疗效和毒副反应。
4) Dopafei(Docetaxel)
多帕菲(多西他赛)
5) Docetaxel for injection
注射用多西他赛
1.
Determination of the content and related substances in Docetaxel for injection by HPLC;
HPLC测定注射用多西他赛的含量并检查有关物质
6) Synthesis of Docetaxel
多西他赛的合成
补充资料：多西他赛
分子式：C43H55NO13
分子量：793.99
CAS号：114977-28-5
性质：暂无
制备方法：暂无
用途：抗肿瘤植物药，用于转移性乳腺癌和非小细胞肺癌。
分子量：793.99
CAS号：114977-28-5
性质：暂无
制备方法：暂无
用途：抗肿瘤植物药，用于转移性乳腺癌和非小细胞肺癌。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条